![](https://ml.globenewswire.com/media/1b166f47-afb1-44f1-91be-2d73e97c0ec3/small/arcutis-logo-png.png)
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
Over 200-person sales force to promote ZORYVE (roflumilast) in primary care and pediatric practices Provides access to a large portion of the 7.4 million individuals treated for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis outside of …